Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Affibody CEO Describes Three-Year Growth Plan

Executive Summary

Sten Stovall chats with David Bejker, CEO of Solna, Sweden-based biotech Affibody AB, about development progress for the company's novel class of antibody mimetics, which he says have superior characteristics surpassing monoclonal antibodies (mAbs) and antibody fragments.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register